Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Downgrades BTRS Holdings to Sector Weight

Keybanc analyst Josh Beck downgrades BTRS Holdings (NASDAQ:BTRS) from Overweight to Sector Weight.

byBenzinga Newsdesk

October 6, 2022

1 minute read

Keybanc analyst Josh Beck downgrades BTRS Holdings (NASDAQ:BTRS) from Overweight to Sector Weight.

Stephens & Co. Maintains Overweight on Guardant Health, Lowers Price Target to $90

By Benzinga Newsdesk

November 7, 11:34 AM

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $99 to $90.

Exagen Stock Gains As Q2 Financials Surpass Street Expectations

By Vandana Singh

August 10, 3:09 PM

Exagen Inc (NASDAQ:XGN) shares are moving after the Company’s Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased…

XGN

Williams Industrial Q3 EPS $0.03 Misses $0.11 Estimate, Sales $73.40M Miss $83.45M Estimate

By Benzinga Newsdesk

November 17, 5:19 PM

Williams Industrial (AMEX:WLMS) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. The company reported quarterly sales of $73.40 million which missed

WLMS

Legal
News

Ovid Therapeutics Granted U.S. Patent Titled ‘Methods of treating developmental disorders with gaboxadol’

By Benzinga Newsdesk

August 24, 10:42 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6597&f=G&l=50&d=PTXT&p=132&S1=20210824&OS=20210824&RS=20210824

OVID

Keybanc Downgrades BTRS Holdings to Sector Weight

Related Posts

Stephens & Co. Maintains Overweight on Guardant Health, Lowers Price Target to $90

Exagen Stock Gains As Q2 Financials Surpass Street Expectations

Williams Industrial Q3 EPS $0.03 Misses $0.11 Estimate, Sales $73.40M Miss $83.45M Estimate

Ovid Therapeutics Granted U.S. Patent Titled ‘Methods of treating developmental disorders with gaboxadol’